Publications by authors named "A Embring"
Article Synopsis
- Diffuse midline glioma (DMG) is a highly aggressive brain cancer in children and young adults, with a poor prognosis of less than 10% survival rate after two years; radiotherapy is a key treatment but only offers short-term benefits.
- The REMIT protocol aims to assess the safety and palliative effectiveness of reirradiation for DMG patients, while monitoring various health indicators, including performance status and quality of life.
- The study will also address patient selection bias and standardization issues, with plans to begin patient inclusion in 2024.
Aims: Reirradiation is becoming more frequently used in paediatric tumours of the central nervous system (CNS). To fill the void of clinical guidelines, the Swedish Working Group of Paediatric Radiotherapy compiled consensus guidelines on reirradiation in 2019. The aim of this study was to evaluate the outcome of children reirradiated for CNS tumours since implementing the guidelines.
View Article and Find Full Text PDFIntroduction: Reirradiation has gained increasing interest, as advances in systemic therapy increase the survival of patients with cancer, and modern radiation techniques allow more precise treatments. However, high-quality prospective evidence on the safety and efficacy of reirradiation to guide clinical practice remains scarce. This systematic review evaluates ongoing prospective studies on reirradiation to identify research gaps and priorities.
View Article and Find Full Text PDFBackground And Purpose: As no guidelines for pencil beam scanning (PBS) proton therapy (PT) of paediatric posterior fossa (PF) tumours exist to date, this study investigated planning techniques across European PT centres, with special considerations for brainstem and spinal cord sparing.
Materials And Methods: A survey and a treatment planning comparison were initiated across nineteen European PBS-PT centres treating paediatric patients. The survey assessed all aspects of the treatment chain, including but not limited to delineations, dose constraints and treatment planning.